Compare · NRC vs SYNH
NRC vs SYNH
Side-by-side comparison of NRC Health (NRC) and Syneos Health Inc. (SYNH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NRC and SYNH operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- SYNH is the larger of the two at $9.19B, about 23.5x NRC ($391.9M).
- NRC has hit the wire 2 times in the past 4 weeks while SYNH has been quiet.
- SYNH has more recent analyst coverage (19 ratings vs 0 for NRC).
- Company
- NRC Health
- Syneos Health Inc.
- Price
- $17.18-0.66%
- $42.98+0.01%
- Market cap
- $391.9M
- $9.19B
- 1M return
- +0.73%
- -
- 1Y return
- +59.12%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 2
- 0
- Recent ratings
- 0
- 19
NRC Health
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
Syneos Health Inc.
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services comprising deployment solutions; communications solutions, such as public relations, advertising, and medical communications; and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a partnership with VBI Vaccines Inc. for the commercialization of 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina
Latest NRC
- National Research Corporation filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Ann & Robert H. Lurie Children's Hospital of Chicago Expands Partnership with NRC Health to Strengthen Consumer Insight and Online Reputation Strategy
- Amendment: SEC Form SCHEDULE 13D/A filed by National Research Corporation
- Piedmont Names NRC Health as a Strategic Experience Partner to Support Mission-Driven Growth
- Executive Vice President Rau Jason Russell was granted 60,000 shares (SEC Form 4)
- NRC Health Announces Board Authorization of $60 Million Share Repurchase Program
- SEC Form S-8 filed by National Research Corporation
- SEC Form 10-K filed by National Research Corporation
- NRC Health Provides Business Update
- EVP & Chief Financial Officer Harrison Shane R bought $98,162 worth of shares (8,000 units at $12.27) (SEC Form 4)
Latest SYNH
- Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S.
- Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting
- Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone)
- NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers
- SEC Form 15-12G filed by Syneos Health Inc.
- Syneos Health Tapped PRA Health Sciences' Colin Shannon as the CEO Succeeding Michelle Keefe
- SEC Form 8-K filed by Syneos Health Inc.
- Zulueta Alfonso G returned $150,199 worth of shares to the company (8,356 units at $17.97), closing all direct ownership in the company (SEC Form 4)
- Wilkes David S. returned $213,839 worth of shares to the company (9,836 units at $21.74), closing all direct ownership in the company (SEC Form 4)
- Monaghan Matthew E. returned $850,411 worth of shares to the company (24,640 units at $34.51), closing all direct ownership in the company (SEC Form 4)